Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 8.26 Million USD | -51.14% |
| 2022 | 16.91 Million USD | -8.3% |
| 2021 | 18.44 Million USD | 98.87% |
| 2020 | 9.27 Million USD | 243.05% |
| 2019 | 2.7 Million USD | 19.54% |
| 2018 | 2.26 Million USD | 0.58% |
| 2017 | 2.24 Million USD | 124.9% |
| 2016 | 1 Million USD | 0.0% |
| 2015 | 1 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 5.62 Million USD | -4.24% |
| 2024 Q1 | 5.87 Million USD | -4.07% |
| 2023 Q3 | 15.42 Million USD | -1.38% |
| 2023 FY | 8.26 Million USD | -51.14% |
| 2023 Q1 | 15.86 Million USD | -6.24% |
| 2023 Q2 | 15.64 Million USD | -1.37% |
| 2023 Q4 | 8.26 Million USD | -46.43% |
| 2022 Q4 | 16.91 Million USD | 15.07% |
| 2022 Q3 | 14.7 Million USD | -1.52% |
| 2022 FY | 16.91 Million USD | -8.3% |
| 2022 Q1 | 17.1 Million USD | -7.3% |
| 2022 Q2 | 14.92 Million USD | -12.71% |
| 2021 Q3 | 14.95 Million USD | -0.55% |
| 2021 Q4 | 18.44 Million USD | 23.35% |
| 2021 Q1 | 17 Million USD | 83.34% |
| 2021 FY | 18.44 Million USD | 98.87% |
| 2021 Q2 | 15.03 Million USD | -11.58% |
| 2020 Q4 | 9.27 Million USD | 1.18% |
| 2020 FY | 9.27 Million USD | 243.05% |
| 2020 Q3 | 9.16 Million USD | 0.0% |
| 2019 Q3 | 3.07 Million USD | 16.15% |
| 2019 Q4 | 3.07 Million USD | 0.0% |
| 2019 FY | 2.7 Million USD | 19.54% |
| 2019 Q1 | 2.58 Million USD | 4.4% |
| 2019 Q2 | 2.64 Million USD | 2.32% |
| 2018 FY | 2.26 Million USD | 0.58% |
| 2018 Q4 | 2.47 Million USD | 2.48% |
| 2018 Q3 | 2.41 Million USD | 2.55% |
| 2018 Q2 | 2.35 Million USD | 2.57% |
| 2018 Q1 | 2.29 Million USD | 2.09% |
| 2017 FY | 2.24 Million USD | 124.9% |
| 2017 Q1 | 1 Million USD | 0.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q3 | 2.15 Million USD | 0.0% |
| 2017 Q4 | 2.24 Million USD | 4.17% |
| 2016 FY | 1 Million USD | 0.0% |
| 2016 Q4 | 1 Million USD | 0.0% |
| 2016 Q3 | 1 Million USD | 0.0% |
| 2016 Q2 | 1 Million USD | 0.0% |
| 2016 Q1 | 1 Million USD | 0.0% |
| 2015 FY | 1 Million USD | 0.0% |
| 2015 Q4 | 1 Million USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -103200.0% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -370.755% |
| Qrons Inc. | 80 Thousand USD | -10230.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 59.315% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -4726.257% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 60.476% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -13992.289% |
| Mesoblast Limited | 100.29 Million USD | 91.76% |
| Marizyme, Inc. | 667.12 Thousand USD | -1138.741% |
| Genus plc | 228.2 Million USD | 96.379% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 95.025% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -149827.431% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -273.937% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -489.051% |
| IMV Inc. | 27.39 Million USD | 69.838% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -52.29% |
| MultiCell Technologies, Inc. | 36.43 USD | -22684500.604% |
| ONE Bio Corp. | 592.19 Thousand USD | -1295.479% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 85.14% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -271.249% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -572.766% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -1390.11% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -32565.323% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -335.298% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -2466.46% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.926% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -5409.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -4932.733% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 46.177% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -185357.81% |
| Genscript Biotech Corporation | 287.12 Million USD | 97.122% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -6443.048% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3504.154% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -3497.877% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -3011.036% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -776591.729% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -5423.547% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -5423.547% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -5760.993% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -5.678% |
| SYBLEU INC | 300 Thousand USD | -2654.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -2139.269% |
| International Stem Cell Corporation | 445 Thousand USD | -1757.079% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1.399% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -1708.315% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -611.8% |
| PureTech Health plc | 18.25 Million USD | 54.718% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -5409.333% |
| IXICO plc | 275 Thousand USD | -2905.091% |
| IntelGenx Technologies Corp. | 11.83 Million USD | 30.197% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 68.589% |
| CSL Limited | 11.23 Billion USD | 99.926% |
| Cellectis S.A. | 36.21 Million USD | 77.178% |